PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 70.5M 6.5M 543M | Sales 2025 * | 511M 47.09M 3.93B | Capitalization | 1.83B 169M 14.12B |
---|---|---|---|---|---|
Net income 2024 * | -305M -28.12M -2.35B | Net income 2025 * | 175M 16.14M 1.35B | EV / Sales 2024 * | 27.3 x |
Net Debt 2024 * | 87.22M 8.04M 672M | Net cash position 2025 * | 119M 10.97M 916M | EV / Sales 2025 * | 3.36 x |
P/E ratio 2024 * |
-6.6
x | P/E ratio 2025 * |
9.17
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 16/17/16 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31/17/31 |
Chief Tech/Sci/R&D Officer | - | 05/22/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01/21/01 |
Director/Board Member | 50 | 01/20/01 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |